Dr Mark Parry-Billings named CEO of Topigen
This article was originally published in Scrip
Executive Summary
Topigen Pharmaceuticals, a clinical-stage biopharmaceutical company specialising in developing products for respiratory disorders, has named Dr Mark Parry-Billings chief executive officer. Dr Parry-Billings joined the company in 2007 as chief development officer and expanded his role to lead the company's operations in early 2008.